Compare PNTG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | CRVS |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2019 | 2016 |
| Metric | PNTG | CRVS |
|---|---|---|
| Price | $40.46 | $12.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $37.00 | $30.17 |
| AVG Volume (30 Days) | 201.0K | ★ 740.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 48.04 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $947,705,000.00 | N/A |
| Revenue This Year | $24.72 | N/A |
| Revenue Next Year | $7.61 | N/A |
| P/E Ratio | $81.57 | ★ N/A |
| Revenue Growth | ★ 36.31 | N/A |
| 52 Week Low | $22.26 | $5.70 |
| 52 Week High | $42.69 | $26.95 |
| Indicator | PNTG | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 37.00 |
| Support Level | $38.50 | $12.76 |
| Resistance Level | $40.55 | $14.00 |
| Average True Range (ATR) | 1.20 | 0.58 |
| MACD | 0.24 | -0.18 |
| Stochastic Oscillator | 91.34 | 18.59 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.